secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001213900-24-027373
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive reports FY2023 net loss of $31.4M; OLC topline data expected Q2 2024
------------------------------------------------------------------------------

- FY2023 net loss $31.4M ($1.28/share) vs $18.1M ($1.20/share) in FY2022.
- Cash $9.7M at Dec 31, 2023; subsequent $50M private placement extends runway into 2026.
- Pivotal OLC trial enrollment completed; topline data expected in Q2 2024.
- UNI-494 granted FDA Orphan Drug Designation for delayed graft function; Phase 1 SAD complete, MAD ongoing.
- R&D expenses $12.9M, G&A $8.5M; licensing revenue $0.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/0001213900-24-027373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024027373/ea0202810-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-027373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer